Integer Holdings Corporation First Quarter 2025 Earnings Conference Call April 24, 2025 Integer Holdings Corporation First Quarter 2025 Earnings Conference Call 9 a.m. Eastern Time, April 24, 2025 Management Attendees: Diron Smith Executive Vice President, Chief Financial Officer Sanjiv Arora Senior Vice President, Strategy, Business Development & Investor Relations ITGR: 1Q25 Earnings Conference Call | April 24, 2025 | Page 2 Joe Dziedzic President, Chief Executive Officer Payman Khales President and CEO E ...

Financial Data and Key Metrics Changes - In Q1 2025, Integer Holdings Corporation reported sales of $437 million, reflecting a 7% year-over-year increase on a reported basis and a 6% increase on an organic basis [20][13] - Adjusted operating income grew by 14%, with adjusted net income reaching $46 million, up 19% year-over-year, and adjusted earnings per share totaled $1.31, up 15% from the same period last year [22][25] - The company reiterated its sales outlook for 2025, expecting reported growth of 8% to 10% and organic growth of 6% to 8% [14][32] Business Line Data and Key Metrics Changes - Cardiovascular sales increased by 17% in Q1 2025, driven by new product ramps in electrophysiology and contributions from recent acquisitions [22] - Cardiac rhythm management and neuromodulation sales grew by 2% in Q1 2025, with expectations of low to mid-single-digit growth for the full year [23][24] Market Data and Key Metrics Changes - The company expects CNV sales to grow in the mid-teens compared to 2024, while CRM and N sales are projected to grow low to mid-single digits [23][24] - The order book increased to approximately $800 million, reflecting strong demand and new product introductions [82] Company Strategy and Development Direction - Integer Holdings Corporation is focused on building differentiated capabilities and collaborating closely with customers to deliver innovative medical device technologies [12] - The company completed two tuck-in acquisitions, enhancing its service offerings and expanding its capabilities in proprietary coating technologies [17][19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to deliver strong sales growth, citing high visibility to customer demand and ramping programs in high-growth markets [14][40] - The company is managing its debt leverage within a target range of 2.5% to 3.5% times EBITDA, with a strategic refinancing completed to reduce interest expenses [29][30] Other Important Information - The company raised its adjusted net income outlook by $10 million, reflecting the impact of interest expense savings [34] - Cash flow from operations increased by 35% year-over-year to $31 million, with free cash flow improving by $12 million from the prior year [28][37] Q&A Session Summary Question: Impact of tariffs on adjusted operating income - Management confirmed the estimated impact of tariffs for 2025 remains between $1 to $5 million, with efforts to minimize this impact [44][49] Question: Deceleration in CRM segment growth - Management noted fewer selling days as a headwind and expects mid-single-digit growth in the CRM segment moving forward [50][56] Question: Growth in electrophysiology - Management stated that electrophysiology continues to outgrow the market, contributing significantly to overall cardiovascular growth [60][62] Question: Customer inventory levels and potential impacts - Management indicated no significant changes in customer ordering patterns related to tariffs, viewing any potential changes as timing issues [128][130] Question: Resilience in a recessionary environment - Management expressed confidence in the company's resilience during economic downturns, noting that most therapies supported are not elective [142][145]

Integer (ITGR) came out with quarterly earnings of $1.31 per share, beating the Zacks Consensus Estimate of $1.27 per share. This compares to earnings of $1.14 per share a year ago. These figures are adjusted for non- recurring items. This quarterly report represents an earnings surprise of 3.15%. A quarter ago, it was expected that this medical device outsource manufacturer would post earnings of $1.46 per share when it actually produced earnings of $1.43, delivering a surprise of -2.05%. Over the last fou ...

EXHIBIT 99.1 Integer Holdings Corporation Reports First Quarter 2025 Results ~ Strong start to the year with 1Q25 financial results ~ ~ Reiterating 2025 sales and adjusted operating income outlook; raising adjusted EPS outlook ~ "Integer started the year off strong with first quarter 2025 sales growing at 7% year-over-year as we continue to execute our strategy by launching new products and adding capabilities in targeted growth markets. Integer also delivered 14% adjusted operating income growth," said Jos ...

Leadership Transition - Joseph Dziedzic will retire as President and CEO of Integer Holdings Corporation effective October 24, 2025, and will step down from the Board of Directors [1] - Payman Khales, currently the Chief Operating Officer, will assume the role of President and CEO and join the Board at that time [1] - To ensure a smooth transition, Dziedzic will serve as an advisor to the company until March 31, 2026 [1] Achievements and Strategy - Dziedzic's leadership over the past eight years has driven significant growth and value creation for Integer, focusing on high-growth markets and unmet patient needs [2] - Under Dziedzic, the company accelerated investments in differentiated technologies and implemented the Integer Production System to enhance manufacturing consistency [2] - Integer is currently achieving above-market organic sales growth with expanding margins, positioning the company for continued growth [2] Incoming CEO Profile - Payman Khales has been with Integer since 2018, initially as President of the Cardio & Vascular business, where he successfully doubled sales in seven years [3][5] - As COO, Khales has overseen both of Integer's business units and has been integral to the development and execution of the company's strategy [3][5] - Khales holds an Executive MBA from Indiana University's Kelley School of Business and a Bachelor of Science in Mechanical Engineering from École Polytechnique de Montréal [6] Company Overview - Integer Holdings Corporation is a leading medical device contract development and manufacturing organization, serving cardiac rhythm management, neuromodulation, and cardio and vascular markets [7] - The company is committed to enhancing patient lives through innovative, high-quality products and solutions, with brands including Greatbatch Medical and Lake Region Medical [7]

~ Strong start to the year with 1Q25 financial results ~ ~ Reiterating 2025 sales and adjusted operating income outlook; raising adjusted EPS outlook ~ PLANO, Texas, April 24, 2025 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR) today announced results for the three months ended March 28, 2025. First Quarter 2025 Highlights (compared to First Quarter 2024, except as noted) "Integer started the year off strong with first quarter 2025 sales growing at 7% year-over-year as we continue to execute o ...

Core Insights - Integer (ITGR) is expected to report quarterly earnings of $1.27 per share, reflecting an 11.4% increase year-over-year, with revenues projected at $431.84 million, a 4.1% increase from the previous year [1] - Over the last 30 days, the consensus EPS estimate has been revised upward by 1.6%, indicating a positive reassessment by analysts [1][2] Revenue Estimates - Analysts predict 'Sales- Medical Sales- Cardiac Rhythm Management & Neuromodulation' to reach $162.26 million, showing a year-over-year increase of 3.8% [4] - 'Sales- Medical Sales- Advanced Surgical, Orthopedics & Portable Medical' is estimated at $22.58 million, reflecting a significant decline of 22.5% from the prior-year quarter [4] - 'Sales- Medical Sales- Cardio & Vascular' is expected to be $247.02 million, indicating an 11.4% increase compared to the same quarter last year [5] Market Performance - Integer shares have decreased by 1.5% over the past month, contrasting with the Zacks S&P 500 composite's decline of 8.9% [6] - The company holds a Zacks Rank of 3 (Hold), suggesting it is likely to perform in line with the overall market in the near term [6]

Core Viewpoint - Integer Holdings Corporation is addressing the impact of tariffs on its business, estimating a potential effect of $1 to $5 million on full year adjusted operating income due to recent trade policy developments [2][6]. Company Overview - Integer Holdings Corporation (NYSE:ITGR) is a leading contract development and manufacturing organization in the medical device sector, focusing on cardiac rhythm management, neuromodulation, and cardiovascular markets [4]. - The company is recognized as a strategic partner for medical device companies and OEMs, committed to enhancing patient lives through innovative and high-quality products [4]. Financial Impact - The estimated impact of tariffs on Integer's adjusted operating income incorporates both currently applicable tariffs and additional tariffs announced on April 2, which will take effect after a 90-day pause [2]. - The company plans to release its financial and operational results for the first quarter of 2025 on April 24, 2025 [3].

Core Points - Integer Holdings Corporation plans to release its financial and operational results for the first quarter of 2025 on April 24, 2025, at 7 a.m. CT / 8 a.m. ET [1] - Following the results release, a webcast will be hosted by Integer management at 8 a.m. CT / 9 a.m. ET to discuss the results and other forward-looking information [1] - Integer is one of the largest medical device contract development and manufacturing organizations (CDMO) globally, focusing on cardiac rhythm management, neuromodulation, and cardio and vascular markets [4] Conference Call Details - An audio replay of the conference call will be available for seven days, accessible by dialing (800) 770-2030 or (609) 800-9909 with Conference ID 3120125 [2] - The conference call will also be available live or via archived replay on the Investor Relations section of the Integer website [2][3] - Domestic and international dial-in numbers for the conference call are provided, along with the Conference ID [5] Company Overview - Integer Holdings Corporation is committed to enhancing patient lives by providing innovative, high-quality products and solutions [4] - The company serves as a strategic partner to medical device companies and OEMs, with notable brands including Greatbatch Medical® and Lake Region Medical® [4]

Core Viewpoint - Integer Holdings Corporation has successfully closed a $1.0 billion offering of 1.875% convertible senior notes due 2030, which is expected to enhance its capital structure and reduce interest expenses, thereby positively impacting adjusted earnings for 2025 [1][2]. Financial Impact - The offering was upsized from an initial $750 million to $875 million due to strong investor demand, with an additional $125 million purchased by initial purchasers [1][2]. - The transaction is projected to lower interest expenses by approximately $12 million in 2025, based on current outstanding debt and interest rates [2]. - The estimated net proceeds from the offering will be $976.1 million after deducting discounts and expenses, which will be used for various financial obligations including repaying existing debt [2]. Strategic Objectives - The transaction creates revolver capacity, allowing the company to continue its tuck-in acquisition strategy while maintaining a targeted leverage range of 2.5 to 3.5 times adjusted EBITDA [2]. - The structure of the convertible notes and associated capped calls is designed to mitigate potential dilution for investors in the future [2][3]. Conversion Details - Upon conversion, the principal amount of the notes will be paid in cash, with an effective conversion price set at $189.44, representing a 60% premium over the company's common stock closing price of $118.40 on March 13, 2025 [3]. - The company has the option to minimize future dilution by delivering the value of any conversion obligation owed in cash or a combination of cash and shares [3]. Company Overview - Integer Holdings Corporation is a leading medical device contract development and manufacturing organization, serving various markets including cardiac rhythm management and neuromodulation [4]. - The company is committed to providing innovative, high-quality products and solutions to enhance patient lives globally [4].